On December 27, 2022 Deka Biosciences, Inc. (Deka), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on December 23, 2022 (Press release, Deka Biosciences, DEC 27, 2022, View Source [SID1234625620]). The IND application supports Deka’s DK210 (EGFR), a promising new cancer treatment that combines normal interleukin-2 with a high affinity interleukin-10, that is designed to accumulate in tumors by binding to the epidermal growth factor receptor (EGFR).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"With no dual cytokine therapy currently approved for the treatment of cancer, this IND application brings us one step closer to fulfilling our mission – to bring cures to patients with cancer and inflammatory diseases," said John Mumm, CEO & Co-Founder of Deka. "We are thrilled to advance DK210 (EGFR) to the clinical phase and anticipate beginning our Phase 1 trial as soon as possible after the FDA’s acceptance of our IND."
The IND filing comes nearly 18 months after the discovery of DK210 (EGFR), and the company is projecting to dose its first patient in early 2023.
DK210 (EGFR) is the first of many experimental therapeutics developed as part of Deka’s platform of molecules. Each Diakine in Deka’s platform consists of two complementary cytokines coupled together via attachment to a single chain variable fragment that enables the cytokines to accumulate more specifically in targeted tissues. The combination of the two cytokines increases potency and reduces toxicity while the targeting system also improves the drug’s efficacy, safety, and manufacturability. Deka has also identified genetic markers that are related to the differentiated responses to each Diakine. These markers will be evaluated in early clinical trials with the hope of using them as potential diagnostic tools to match patients with the most effective Diakine treatment in later stage trials.